Try to Continue the New Cystic Fibrosis Meds During a Hospital Stay

May 2018

Tezacaftor/ivacaftor (Symdeko, SIM-deh-koh) will raise questions about handling new cystic fibrosis (CF) meds during a hospital stay.

Symdeko joins other CF transmembrane conductance regulator (CFTR) modulators...lumacaftor/ivacaftor (Orkambi) and ivacaftor (Kalydeco).

Expect to see more patients on these game-changing meds...since they'll be first-line agents for patients who qualify.

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote